• ANI Pharmaceuticals reaffirmed 2026 guidance for total net revenue of $1.08 billion-$1.14 billion; adjusted non-GAAP EBITDA of $285 million-$300 million.
• Cortrophin Gel net revenue outlook reset to $520 million-$540 million from $540 million-$575 million; ILUVIEN guidance kept at $78 million-$83 million.
• Adjusted non-GAAP diluted EPS forecast maintained at $9.19-$9.69; adjusted non-GAAP gross margin expected at 59.9%-60.9%.
• Rare Disease expected to approach about 60% of 2026 revenue, with Cortrophin positioned as the main multi-year growth driver.
• Gout expansion became fully operational by end-June; Rare Disease sales force expanded about 50% to roughly 180 representatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.